As of close of business last night, Recursion Pharmaceuticals Inc’s stock clocked out at $15.52, up 5.15% from its previous closing price of $14.76. In other words, the price has increased by $+0.76 from its previous closing price. On the day, 12479856 shares were traded.
Ratios:
To gain a deeper understanding of RXRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.28 and its Current Ratio is at 4.28. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 22 when Marriott Tina sold 8,000 shares for $14.89 per share. The transaction valued at 119,160 led to the insider holds 639,982 shares of the business.
Borgeson Blake sold 20,054 shares of RXRX for $247,125 on Feb 20. The Director now owns 7,292,863 shares after completing the transaction at $12.32 per share. On Feb 14, another insider, Secora Michael, who serves as the Chief Financial Officer of the company, sold 25,000 shares for $10.46 each. As a result, the insider received 261,425 and left with 1,186,351 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 3.35B and an Enterprise Value of 3.01B. For the stock, the TTM Price-to-Sale (P/S) ratio is 70.74 while its Price-to-Book (P/B) ratio in mrq is 7.64. Its current Enterprise Value per Revenue stands at 64.15 whereas that against EBITDA is -11.05.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $16.75, while it has fallen to a 52-week low of $4.54. The 50-Day Moving Average of the stock is 10.72, while the 200-Day Moving Average is calculated to be 8.90.
Shares Statistics:
It appears that RXRX traded 6.35M shares on average per day over the past three months and 10.89M shares per day over the past ten days. A total of 183.21M shares are outstanding, with a floating share count of 146.52M. Insiders hold about 32.13% of the company’s shares, while institutions hold 77.22% stake in the company. Shares short for RXRX as of Jan 31, 2024 were 38.27M with a Short Ratio of 6.03, compared to 37.04M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 17.73% and a Short% of Float of 27.85%.
Earnings Estimates
As of right now, 8 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.45 for the current quarter, with a high estimate of -$0.3 and a low estimate of -$0.59, while EPS last year was -$0.31. The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.39 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.57 and -$1.76 for the fiscal current year, implying an average EPS of -$1.64. EPS for the following year is -$1.85, with 8 analysts recommending between -$1.51 and -$2.3.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $20.35M. It ranges from a high estimate of $56.32M to a low estimate of $12M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $13.68M, an estimated increase of 48.80% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $14.4M, an increase of 18.70% less than the figure of $48.80% in the same quarter last year. There is a high estimate of $20.6M for the next quarter, whereas the lowest estimate is $12.5M.
A total of 8 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $90M, while the lowest revenue estimate was $38.5M, resulting in an average revenue estimate of $52.14M. In the same quarter a year ago, actual revenue was $39.84M, up 30.90% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $59.06M in the next fiscal year. The high estimate is $82.6M and the low estimate is $43M. The average revenue growth estimate for next year is up 13.30% from the average revenue estimate for this year.
